Spago Nanomedical
6.12.2021 08:21:33 CET | ACCESS Newswire | Press release
LUND, SWEDEN / ACCESSWIRE / December 6, 2021 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)
Spago Nanomedical AB (publ) today announced it has completed the studies in the regulatory preclinical program with its leading candidate drug Tumorad (SN201). It displays a good safety margin to clinically relevant doses.
"The completion of the regulatory preclinical studies is an important step towards the clinical development phase. The preparations for the first study with SN201 in humans are proceeding according to plan and we expect to be ready to start phase I/II in next year ", said CEO Mats Hansen.
The preclinical package included toxicology- and dosimetry-studies in rat. The results showed that the nanomaterial is safe to give in doses that widely exceed planned clinical doses, and that radiation is distributed in the body in a manner that allow dosing according to plan.
"The results confirm the data we previously have seen in pilot studies and mean that we with confidence can proceed with SN201 to the clinic. This is a major risk reduction in the project ", said Oskar Axelsson, CSO at Spago Nanomedical.
Data from the preclinical studies, together with other documentation, will form the basis for the first clinical trial application with Tumorad. The plan is to submit the application and start the studies in humans in 2022. The aim for the clinical study is to document safety at different doses of Tumorad in cancer patients as well as to evaluate signs of early proof-of-concept.
The preclinical regulatory program, conducted in collaboration with Charles River Laboratories and Minerva Imaging, included both toxicity and dosimetry studies.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, info@fnca.se .
This information is information that Spago Nanomedical is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-06 08:00 CET.
Attachments
Tumorad® shows good safety in preclinical studies
SOURCE: Spago Nanomedical
View source version on accesswire.com:
https://www.accesswire.com/676127/TumoradR-Shows-Good-Safety-in-Preclinical-Studies
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Reports Q4 2025 and Full Year 2025 Record Results, and Upward Revisions to Full Year 2026 Outlook26.2.2026 14:30:00 CET | Press release
WHITE PLAINS, NY / ACCESS Newswire / February 26, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reports record results for the fourth quarter and full year of 2025 and upward revisions to the full year 2026 outlook. "As we close the year, I am pleased to report that Loar once again delivered record results across key financial metrics, including Net Sales, Adjusted EBITDA, and Adjusted EBITDA Margin," said Dirkson Charles, Loar CEO and Executive Co‑Chairman of the Board of Directors. "Driven by favorable end‑market dynamics and disciplined execution across the organization, our team delivered strong operating performance while advancing our long‑term value creation strategy. These results underscore the scalability and resilience of our business model and reinforce Loar's position as a leading aerospace and defense component supplier. We also successfully completed the acquisitions of LMB Fans & Motors and Harper Engineering, further strengthening
U.S. Polo Assn. Returns as Official Apparel and Jersey Sponsor of the 2026 Dubai Polo Gold Cup for Third Consecutive Year26.2.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL AND DUBAI, UAE / ACCESS Newswire / February 26, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly served as the Official Apparel and Jersey Sponsor of the 2026 Dubai Polo Gold Cup, held January 28 through February 14 at the renowned Al Habtoor Polo Club in Dubai, United Arab Emirates.Dubai Wolves by Thera with their trophy on stage at the Dubai Polo Gold Cup 2026 at the Al Habtoor Polo Club Photo Credit: Margarita Crotto Now marking its third consecutive year supporting the prestigious tournament, U.S. Polo Assn. provided custom performance jerseys to participating teams, apparel for event staff, and exclusive player prizes for the finalists. Spectators joined in the excitement during the traditional divot stomp with a special U.S. Polo Assn. cap giveaway, adding a spirited fan moment to the two-week competition in the UAE. The 2026 Dubai Polo Gold Cup Final delivered an electrifying showdown of world-renowned pl
Innovation Holds Key to Future Growth, New Research from Ipsos, Alchemy-RX and Market Logic Finds26.2.2026 10:00:00 CET | Press release
Global organisations are doubling down on innovation and consumer understanding, as they look to grow revenues in the next three years. LONDON, UK / ACCESS Newswire / February 26, 2026 / A new study, Innovation Reignited: C-Suite insights on the state of innovation, from Ipsos, Alchemy-RX and Market Logic reveals that innovation is rapidly becoming the cornerstone of corporate growth strategies worldwide. According to the findings of the survey of C-Suite executives, 82% of companies expect innovation to drive growth strategy. Still, only the most ambitious leaders (33%) anticipate this will account for more than 20% of revenue in the next three years. However, with respondents reporting that less than 75% of innovation launches meet all their launch goals, the risk of missing ambitious growth targets is significant for those who do not optimise their innovation processes. Deeper customer understanding is key While the need to adopt a customer-centric approach to every stage of innovat
Telestream Advances Production-Ready AI Across Its Product Portfolio26.2.2026 09:00:00 CET | Press release
New AI capabilities drive smarter automation, enriched metadata, and assisted workflow design for live and file-based workflows on-premises and in the cloud NEVADA CITY, CA / ACCESS Newswire / February 26, 2026 / Telestream, global leader in media workflow technologies, today announced expanded practical AI enhancements across its Vantage, Vantage Cloud, EDC, Stanza, and Qualify product lines. Building on the foundation introduced with Vantage AI in 2025, Telestream is advancing its production-ready AI workflows, accelerating localization, strengthening quality control, and introducing new AI-assisted workflow design capabilities that connect and unify enterprise operations across on-premises, cloud, and hybrid environments. The latest enhancements reflect a shift from introducing AI features to operationalizing AI across the enterprise, driving measurable workflow impact across ingest, processing, compliance, and delivery. "Last year we introduced Vantage AI as a new foundation for in
Tech "Talent Wars" Are Over as More Companies Prioritize Upskilling, General Assembly Report Finds25.2.2026 15:00:00 CET | Press release
83% of tech recruiters believe company success is more dependent on upskilling employees for AI versus hiring new talent, according to The State of Tech Talent 2026 NEW YORK CITY, NY / ACCESS Newswire / February 25, 2026 / Nearly all technology recruiters (96%) say technical roles are still at least a bit difficult to fill, as most (83%) believe their company's success is now more dependent on upskilling their existing employees for AI rather than hiring external talent, according to The State of Tech Talent 2026, the fourth annual report from AI training provider General Assembly, an LHH brand. "The AI skills gap is growing too fast for companies to hire their way out," said Daniele Grassi, CEO of General Assembly. "Continuous, incremental and role-specific learning is the only way to keep up with the pace of technology change. Growing investment in upskilling reflects leaders' realization that their existing employees bring the business context, institutional knowledge and cultural n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom